RxDoctor Payments DataLook up a doctor →

Carolyn Smallwood

Physician Assistant · Birmingham, ALNPI 1578004552

Payments from drug & device makers

$9,265in general payments, 2019–2025

Across 513 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$905
  • Neurocrine Biosciences, Inc.$903
  • UCB, Inc.$690
  • TG Therapeutics, Inc.$592
  • Genentech USA, Inc.$588
  • AbbVie$581
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$9,254100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,265 in reported general payments places this provider in the 95th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$119,841
Medicare patients
162
Services billed
3,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab22$203,945
CopaxoneGlatiramer Acetate18$113,354
Teriflunomide19$54,763
Glatiramer Acetate26$46,238
Emgality PenGalcanezumab-Gnlm38$27,507
Nurtec OdtRimegepant Sulfate17$25,729
Aimovig AutoinjectorErenumab-Aooe34$25,136
QuliptaAtogepant13$16,050
Dalfampridine ErDalfampridine40$15,038
UbrelvyUbrogepant14$13,825
Dimethyl Fumarate25$13,010
Carbidopa-LevodopaCarbidopa/Levodopa64$2,613
Pyridostigmine Bromide35$2,397
Carbidopa-Levodopa ErCarbidopa/Levodopa25$2,353
Baclofen122$2,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$14$113,35418 claims
AbbVieQulipta, Ubrelvy$581$29,87527 claims
PfizerNurtec Odt$514$25,72917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →